ScholarIQanswers from OpenAlex & ORCID
M. Pérol
ResearcherPublications, citations & collaboration network
M. Pérol is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does M. Pérol have?
ScholarIQindexed works
M. Pérol has 622 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does M. Pérol have?
ScholarIQcitation count
M. Pérol has 19,926 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of M. Pérol?
ScholarIQh-index
M. Pérol has an h-index of 59 in OpenAlex.
What is the i10-index of M. Pérol?
ScholarIQi10-index
M. Pérol has an i10-index of 177 in OpenAlex.
What is the ORCID of M. Pérol?
ScholarIQorcid
The ORCID for M. Pérol is on the source record.
What is the OpenAlex record for M. Pérol?
ScholarIQopenalex
The OpenAlex for M. Pérol is on the source record.
What are the most-cited papers on M. Pérol?
ScholarIQmost cited works
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, Jose M. Pacheco, M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Jänne
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, D.-W. Kim, M. Pérol, S.-H.I. Ou, Jin Seok Ahn, A. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, Johannes Noé, Solange Peters
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières